Drug Discovery World

SEPTEMBER 22, 2023

As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.

Vaccine 130

Vaccine Clinical Trials Virus Drugs 130

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Discovery World

FEBRUARY 24, 2023

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The trial also evaluated the efficacy of HTI vaccines in combination with VES to avoid, delay or contain viral rebound compared to a placebo group.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. Other inhibitors, currently in different stages of development (including clinical trials ), mainly target viral non-structural proteins or the internal ribosome entry site (IRES).

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

JUNE 16, 2023

The top stories: FDA approves Phase III cerebral Adrenoleukodystrophy trial THE FDA has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

FDA Approval 130

FDA Approval Clinical Trials FDA Drugs 130

Drug Discovery World

JUNE 7, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? What changes can we expect from clinical trials? Is it true that the next era will belong to antibody drug conjugates? Will digital therapeutics grow in significance?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 27, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? What changes can we expect from clinical trials? Is it true that the next era will belong to antibody drug conjugates? Will digital therapeutics grow in significance?

DNA 130

DNA Drugs Clinical Trials Vaccine 130

Drug Discovery World

JUNE 22, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? What changes can we expect from clinical trials? Is it true that the next era will belong to antibody drug conjugates? Will digital therapeutics grow in significance?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 15, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? What changes can we expect from clinical trials? Is it true that the next era will belong to antibody drug conjugates? Will digital therapeutics grow in significance?

DNA 130

DNA Drugs Clinical Trials Vaccine 130

Drug Discovery World

JUNE 8, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? What changes can we expect from clinical trials? Is it true that the next era will belong to antibody drug conjugates? Will digital therapeutics grow in significance?

Drugs 130

Drugs DNA Clinical Trials Vaccine 130

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . New combination therapy shows promise against lung cancers? .

DNA 130

DNA Clinical Trials Vaccine Virus 130

Drug Discovery World

FEBRUARY 10, 2023

Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient populations in trials were exposed.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. For example, a site conducting only protocols involving mRNA may be able to leverage a generic SOP covering any mRNA protocol at that site.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

Drug Discovery World

AUGUST 1, 2024

DDW Editor Reece Armstrong speaks to Dr Steven Powell , co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Is there a large unmet need?

Drugs 147

Drugs Clinical Trials Therapies Production 147

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Successful industry/academia collaboration Fewer than 5% of rare diseases have approved therapies and most of these treatments use gene therapy.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

JANUARY 9, 2024

They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among others. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 173

Drugs Therapies Treatment Virus 173

The Pharma Data

SEPTEMBER 23, 2020

The halting of AstraZeneca’s COVID-19 vaccine trial around the world was cause for much initial concern over the eventual safety and efficacy of the therapy. Trials have resumed in the UK, Brazil and South Africa, but US trials remain on hold. Matt Fellows. Source link.

Vaccine 52

Vaccine Trials Science Regulations 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. The phase 1 clinical trial was a randomized, double-blind and placebo-controlled study in 150 adult and elderly participants.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

SEPTEMBER 12, 2020

Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations. The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. If successful, this trial could enable the inclusion of a pediatric population in the Phase 3 trial.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

NOVEMBER 22, 2020

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. Trials are also being run in the U.S.,

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About the Phase 1/2/3 Trial in Children.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Drug Discovery World

FEBRUARY 28, 2024

Using IgE to treat cancer In the UK, a Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. “Cancer shredding could hold potential not only for glioblastoma, but possibly for other hypermutated tumours.”

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

APRIL 15, 2023

BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. VAL-083, is a ‘first-in-class’ small-molecule chemotherapeutic with a novel mechanism of action that targets DNA and crosses the blood brain barrier to inhibit cancer cell replication and cell division.

Virus 130

Virus Clinical Trials Trials Therapies 130

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–( This press release features multimedia.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October.

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Virus Hospitals Trials 40

Drug Discovery World

SEPTEMBER 13, 2023

27% of patients with non-vaccinal SARS-COV-2 positive serology corresponded to the previously described psychotic disorder subgroup associating HERV-W expression. The first months of the trial have already confirmed that the W-ENV protein is present in the blood of over 25% of patients with persistent syndromes who suffered from Long Covid.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

The Pharma Data

JANUARY 6, 2021

6 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunisation of adults. Additional safety and efficacy data will continue to accumulate from ongoing clinical trials.

Vaccine 52

Vaccine Virus Clinical Trials Government 52